Introduction/Background Uterine carcinosarcomas are considered highly aggressive tumors associated with a poor prognosis. They associate carcinomatous and sarcomatous elements and arise from a single malignant clone. They represent rare gynecological tumors.

Methodology A monocentric retrospective study was conducted over a period of 7 years between 2017 and 2023 at the oncology department of Salah Azaiez Institute. Our study concerns women with uterine carcinosarcomas. All data regarding patients were obtained from the medical records.

Results Twenty-five patients were included. The median age was 64 years.The main symptom was postmenopausal metrorrhagia (96%). FIGO staging was respectively Stage I-II in 44% of the patients, Stage III in 32% and Stage IV in 24%. Surgery was performed in all patients. Four patients received neoadjuvant chemotherapy. 56% had complete resection, 24% had R1 resection and 20% R2 resection. 72% of patients had chemotherapy. Paclitaxel carboplatin was the most frequently used regimen. 52% of patients died mainly because of the progressive disease except for 3 cases due to complications after treatment with 1 anastomotic release post-surgery and 2 thromboembolic events. During follow-up, 12% of the patients relapsed after optimal treatment with mainly local and vaginal relapse. The majority of the patients alive (75%) had localized disease. The median survival was 22 months. The overall survival at 2 years was 46%.

Conclusion Uterine carcinosarcomas are aggressive tumors. Even with the association of surgery, chemotherapy and radiotherapy, the mortality rate is still high. It is important to optimize treatment to prevent the dissemination and improve the overall survival.

Disclosures We have no conflicts of interest to disclose. All authors declare that they have no conflicts of interest.